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Deregulation ofapoptosisiscommon incancerandisoftencausedbyoverexpressionofanti-apoptoticproteins intumour cells.
One important regulator of apoptosis is the cellular FLICE-inhibitory protein (c-FLIP), which is overexpressed, for example, in
melanoma and Hodgkin’s lymphoma cells. Here, we addressed the question whether deregulated c-FLIP expression in urothelial
carcinoma impingesonthe abilityofdeathligandstoinduce apoptosis.Inparticular,weinvestigated theroleofthec-FLIPsplice
variants c-FLIPlong (c-FLIPL) and c-FLIPshort (c-FLIPS), which can have opposing functions. We observed diminished expression
of the c-FLIPL isoform in urothelial carcinoma tissues as well as in established carcinoma cell lines compared with normal
urothelial tissues and cells, whereas c-FLIPS was unchanged. Overexpression and RNA interference studies in urothelial cell
lines nevertheless demonstrated that c-FLIP remained a crucial factor conferring resistance towards induction of apoptosis by
death ligands CD95L and TRAIL. Isoform-speciﬁc RNA interference showed c-FLIPL to be of particular importance. Thus,
urothelialcarcinomacellsappeartoﬁne-tunec-FLIPexpressiontoalevelsufﬁcientforprotectionagainstactivationofapoptosis
by the extrinsic pathway. Therefore, targeting c-FLIP, and especially the c-FLIPL isoform, may facilitate apoptosis-based
therapies of bladder cancer in otherwise resistant tumours.
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Apoptosis is a controlled form of cell death, which is essential
for normal development and the maintenance of tissue
homeostasis in multicellular organisms. Deregulation of
apoptosis disturbs the balance between the proliferation
and death of cells, with too much proliferation leading to
tumour formation and cancer.
1 Upregulation of anti-apoptotic
cellular FLICE inhibitory proteins (c-FLIPs) have been
demonstrated in different types of cancer.
2 Several mRNA
isoforms of c-FLIP have been reported, from which three
protein isoforms are expressed, namely c-FLIPlong (c-FLIPL),
c-FLIPshort (c-FLIPS) and c-FLIPRaji (c-FLIPR).
3–5 c-FLIPL
resembles procaspase-8 with two death effector domains
(DEDs) and a catalytically inactive caspase-like domain. The
two shorter isoforms, c-FLIPS and c-FLIPR, mainly consist of
the DEDs with a truncated C-terminal end. Interestingly, a
functional single nucleotide polymorphism (SNP) regulates
whether c-FLIPS or FLIPR is produced in humans.
6 The FLIP
proteins can modulate apoptosis in close proximity to death
receptors such as CD95 (Fas/Apo-1), tumour necrosis factor
(TNF) receptor-1 (TNF-R1), TNF-related apoptosis inducing
ligand (TRAIL) receptor-1 (TRAIL-R1; DR4) and TRAIL-R2
(DR5).
7 The so called death-inducing signalling complex
(DISC) is formed upon triggering of death receptors and
thereby activation of their intracellular domains, which allows
recruitment of an adaptor protein such as FADD (Fas-
associated death domain-containing protein), which, in turn,
can recruit the DED-containing proteins procaspase-8,
procaspase-10 and the different c-FLIP isoforms.
7 The
initiator caspases 8 and 10 become activated upon dimerisa-
tionandproteolyticcleavageattheDISC,initiatingasignalling
cascade resulting in apoptosis.
8–10 The DEDs of c-FLIP allow
recruitment to the DISC,
11 where cleavage of initiator
caspases can be prevented and caspase activation is
consequently inhibited.
3,5,12 Although the short isoforms
c-FLIPS and c-FLIPR have been shown to solely possess
anti-apoptotic functions,
5,11,12 the role of c-FLIPL has been
more controversially discussed.
3,13 c-FLIPL was shown to
exert either proapoptotic or anti-apoptotic functions depend-
ing on its expression level
14,15 and on the strength of CD95
receptor stimulation.
16 Moderate expression of c-FLIPL was
shown to promote apoptosis only upon strong receptor
stimulation or in combination with overexpression of c-FLIPS
or c-FLIPR. In contrast, high levels of c-FLIPL diminished
the sensitivity for CD95-induced apoptosis and caspase-8
activation.
16
As numerous reports have demonstrated upregulation
of c-FLIP in various cancers, prominently Hodgkin’s lym-
phoma
17,18 and melanoma,
4,19 may allow tumours avoiding
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2,20,21 Moreover, upregulation
of c-FLIP has been suggested as a possible mechanism
for resistance to therapeutic triggering of death receptors
and the extrinsic apoptotic pathway, which is studied as a
promising approach to cancer therapy.
22 In particular, the
death receptor ligand TRAIL selectively induces apoptosis in
various tumour cells in vivo without affecting cells in normal
tissues.
23,24 However, more recent studies described resis-
tance against TRAIL-induced apoptosis in many primary
tumour cells.
25
CD95 and TRAIL have also been implicated in the
pathogenesis and response to therapy in bladder cancer.
25,26
In 2010, cancer of the urinary bladder was the fourth most
common cancer in men in the United States as well as in the
EuropeanUnion(EU)andmorethan90%ofthecaseswereof
the urothelial carcinoma histological subtype. Bladder cancer
is primarily treated by surgery. Immunotherapy by BCG is
commonly used to prevent recurrences and is thought to be
mediated partly by effects of neutrophil-derived TRAIL on
residual tumour cells.
27 Cisplatin-based chemotherapy is
used for the treatment of advanced stage cases, but is only
moderately efﬁcacious. In 2008, almost 30000 patients died
ofbladdercancerintheEU.Becauseofthehighmorbidityand
mortality of bladder cancers, there is an urgent need for
improved treatment strategies and in particular, for under-
standing the mechanisms underlying resistance to immuno-
therapy and chemotherapy.
The expression and function of c-FLIP in urothelial cancer
are of obvious interest in that context, but few studies are
available to date. One immunohistochemical study described
an association of strong c-FLIP expression with tumour
progression in bladder cancer, but curiously a lack of
expression in normal urothelium.
28 As many cancers retained
CD95 expression, the authors suggested that c-FLIP might
contribute to resistance against CD95-induced apoptosis.
However, no functional experiments were performed. In
contrast, another study provided evidence that c-FLIPL might
contribute to TRAIL resistance of some urothelial carcinoma
cell lines.
29 Unfortunately, these studies have not been
followed up to date. In particular, the contribution of the
different c-FLIP isoforms to protection of CD95- and TRAIL-
mediated apoptosis in urothelial carcinoma cells has not been
studied. Therefore, we examined the expression of c-FLIPL
and c-FLIPS in primary tumours and cell lines and their
contribution to resistance against death receptor-mediated
apoptosis in urothelial carcinoma cell lines in detail. Surpris-
ingly, we observed that c-FLIPL was decreased in primary
tumours and cell lines compared with normal urothelial tissue
and cells. Nevertheless, urothelial carcinoma cell lines were
resistant towards apoptosis-induction by CD95L or TRAIL,
and required prevention of protein synthesis for sensitisation,
indicating that short-lived proteins such as c-FLIP may
contribute to resistance. Indeed, speciﬁc downregulation of
c-FLIP by RNA interference using short hairpin RNAs
(shRNAs) sensitised urothelial carcinoma cell lines towards
both CD95- and TRAIL-mediated apoptosis. Thus, despite
diminished expression, c-FLIP proteins appear to remain
important resistance factors with respect to apoptosis-based
therapies in bladder cancer.
Results
c-FLIPL expression is decreased in urothelial carcinoma.
We ﬁrst analysed the expression of c-FLIPL and c-FLIPS
mRNA in urothelial carcinoma samples. c-FLIPL mRNA
levels were moderately but signiﬁcantly decreased in
tumour samples compared with normal urothelial tissue
(Figure 1a). Similarly, the expression of c-FLIPL as
quantiﬁed by real-time PCR was lower in urothelial
carcinoma cell lines than in cultured normal urothelial cells
(NUCs, Figure 1b). c-FLIPS were not differentially expressed
between either tissues or cell lines (Figures 1a and b). Of
note, a few tissue samples did not express c-FLIPS at all,
most likely due to the presence of a functional SNP
(rs10190751 A/G) in the c-FLIP gene, which determines
whether c-FLIPR or FLIPS is produced.
6 In the context of the
former study,
6 however, we had not observed signiﬁcant
changes in the distribution of this SNP between bladder
cancer patients and controls (data not shown).
To ﬁnd a suitable cell model for determining whether even
lower levels of c-FLIP can mediate resistance towards death
receptor-mediated apoptosis and to investigate the role of
c-FLIP splice variants in urothelial carcinoma, we next
analysed the urothelial carcinoma cell lines 639v, SD, 647v,
VMCub1, BFTC905 and J82 for c-FLIP protein expression.
Both protein isoforms, c-FLIPL and c-FLIPS, were readily
observed in these cell lines except for 639v cells, in which c-
FLIPSwashardlydetectable(Figure1c).Furthermore,thecell
lines were analysed by ﬂow cytometry analysis and western
blotting to evaluate death receptor expression (Supplemen-
tary Figure 1), sensitivity towards CD95L-induced apoptosis
(data not shown), and the expression of proteins involved in
the ‘extrinsic’ and ‘intrinsic’ apoptotic pathways (Supplemen-
tary Figure 2). The cell lines VMCub1 and SD were chosen for
further experiments based on their death receptor and c-FLIP
expression proﬁle.
Cycloheximide (CHX) sensitises urothelial carcinoma
cell lines towards CD95L- and TRAIL-induced
apoptosis. To investigate whether the extrinsic pathway
can be triggered in VMCub1 and SD, the death receptor
expression of these cell lines was analysed by surface
staining of the death receptors CD95, TRAIL-R1 (DR4),
TRAIL-R2 (DR5) and TNF-R1. VMCub1 cells had a
moderate-to-high expression of CD95, TRAIL-R2 and
TNF-R1, whereas SD cells had a moderate-to-high
expression of all the four death receptors (Figure 1d).
To assess CD95L- and TRAIL-induced apoptosis of
VMCub1 and SD, cells were stimulated with the ligands for
16 and 24h, respectively, before measurement of DNA
fragmentation. Both urothelial carcinoma cell lines showed
low sensitivity towards CD95L-induced (Figure 2a) as well as
TRAIL-induced apoptosis (Figure 2b). However, VMCub1
and SD cells were strongly sensitised towards apoptosis by
addition of the protein translation inhibitor CHX (Figures 2a
and b). An additional measure of apoptosis is caspase
processing as the initiator caspase-8 and the effector
caspase-3 are activated by proteolytic cleavage. For this
purpose, VMCub1 and SD cells were stimulated with CD95L
for up to 8h (Figure 2c) or TRAIL for up to 24h (Figure 2d) in
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Cell Death and Diseasethe absence or presence of CHX, followed by western blot
analysis to examine caspase cleavage as an early event
during apoptosis. There was only minimal cleavage of
caspase-8 and caspase-3 after stimulation with CD95L or
TRAIL alone, whereas the presence of CHX caused
substantial cleavage of both caspases. Taken together, our
results indicate that short-lived proteins have an important
role in protecting the urothelial carcinoma cells against
apoptosis. In particular, at least one short-lived protein
protects against apoptosis at a step before caspase-8
activation, for which c-FLIP is the most likely candidate.
30,31
c-FLIP overexpression protects urothelial carcinoma
cells against apoptosis. To ensure that c-FLIP is indeed
a short-lived protein in urothelial carcinoma cells, we followed
protein levels of c-FLIP after treatment of VMCub1 and SD
cells with CHX (Figure 3a). Consistent with previous
reports,
30,31 a rapid turnover of both c-FLIPL and c-FLIPS
was observed, with c-FLIPL being slightly more stable. This
ﬁnding suggests that the c-FLIP proteins are likely
candidates for the short-lived proteins responsible for the
reduced sensitivity against apoptosis in the urothelial
carcinoma cell lines. As it is known that all three c-FLIP
splice variants can inhibit death receptor-mediated
apoptosis,
3,5,32 we investigated whether overexpression of
any c-FLIP isoform could protect VMCub1 and SD cells
against apoptosis. The three c-FLIP splice variants c-FLIPL,
c-FLIPS and c-FLIPR were cloned into a vector, which allows
tracking of transfected cells by IRES-driven GFP expression.
The generated constructs were ﬁrst transiently transfected
into 293T cells to verify that the respective c-FLIP variants
and in addition GFP were expressed at the protein level
(Figure 3b). We then transiently transfected VMCub1 and SD
cells with either the empty vector or one of the c-FLIP
constructs, stimulated the cells with CD95L and examined
the intracellular levels of active caspase-3 by ﬂow cytometry.
Indeed, both VMCub1 (Figures 3c and d) and SD cells
(Figures 3e and f) were protected by overexpression of any
c-FLIP variant against CD95L-mediated apoptosis. The
protective effect of c-FLIP overexpression was also
conﬁrmed by staining of transfected and stimulated cells
using tetramethylrhodamine ethyl ester (TMRE; data not
shown).
Knockdown of c-FLIP sensitises urothelial carcinoma
cells for CD95L-induced apoptosis. As high expression of
Figure 1 (a) Quantiﬁcation of c-FLIPL and c-FLIPS mRNA levels in normal urothelial tissues (normal; n¼10) and urothelial carcinoma samples (tumour; n¼28) by
real-time RT-PCR. Values were normalised to GAPDH expression. Horizontal lines represent the mean; error bars display the standard deviation. Statistical analyses
were performed by two-tailed Mann–Whitney U-tests. (b) Quantiﬁcation of c-FLIPL and c-FLIPS mRNA levels in NUCs (n¼7) and urothelial cell lines (cell line; n¼19)
by real-time PCR. Values were normalised to TBP expression levels. Horizontal lines represent the mean; error bars display the standard deviation. Statistical analyses
were performed by two-tailed Mann–Whitney U-tests. (c) Western blot analysis of c-FLIP protein expression in the indicated urothelial cell lines. b-Actin was used as the
loading control. (d) VMCub1 and SD cell surface expression of the death receptors CD95, TRAIL-R1, TRAIL-R2 and TNF-R1 analysed by ﬂow cytometry. Unstained cells are
shown in white
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mediated apoptosis,
3,5,32 we followed a loss-of-function
approach to determine speciﬁc functions of the different
c-FLIP splice variants. We used RNA interference and stably
transduced the VMCub1 and SD cells with lentiviral shRNA
constructs targeting c-FLIPL, c-FLIPS or both c-FLIPL/S
isoforms (Supplementary Figure 3). The knockdown of
c-FLIPL was less efﬁcient than the c-FLIPS and c-FLIPL/S
knockdowns. Still, we observed more efﬁcient shRNA
knockdowns in the urothelial cell lines VMCub1 and SD
than in the human T-cell line CEM.
33
As assessed by measurement of DNA fragmentation,
stimulation of VMCub1 and SD knockdown cells with
increasing concentrations of CD95L led to elevated levels of
apoptosisinthec-FLIPL/Sdoubleknockdowncells(Figures4a
and b). The effect was most prominent for the SD cells
expressing shRNAs targeting both c-FLIPL and c-FLIPS,
where the extent of apoptosis was comparable to those of
wild-type SD cells treated with CHX (Figure 2a). This ﬁnding
strongly supports the argument that c-FLIP is a prominent
short-lived anti-apoptotic protein in these cells. Moreover, SD
cellswithknockdownofc-FLIPLalonewere highlysusceptible
towards CD95L-induced apoptosis, whereas SD cells with
knockdown of c-FLIPS alone remained resistant (Figure 4b).
VMCub1 cells with single knockdown of c-FLIPL or c-FLIPS
showed a mild, but statistically signiﬁcant increase in CD95L-
mediated apoptosis (Figure 4a). The effects of c-FLIPL or
c-FLIPS knockdown on DNA fragmentation was paralleled by
effects on caspase processing. The most extensive cleavage
of caspase-8 and caspase-3 was observed in VMCub1 and
SD c-FLIPL/S double knockdown cells as well as SD c-FLIPL
single knockdown cells, where the proform of caspase-8 was
extensively processed to the cleavage products p41/43 and
p18 of caspase-8 as well as p17/20 of caspase-3 (Figures 4c
and d). In contrast, both caspase-8 and caspase-3 remained
uncleaved in VMCub1 and SD cells transduced with scramble
shRNA. Thus, c-FLIP proteins protect the urothelial carcino-
ma cells against CD95L-induced apoptosis. Furthermore, the
long c-FLIP isoform appears to be more important.
Urothelial carcinoma cells are sensitised for TRAIL-
induced apoptosis by knockdown of c-FLIP. We also
investigated the effect of isoform-speciﬁc c-FLIP knockdown
on TRAIL-induced apoptosis in VMCub1 and SD cells.
Susceptibility to TRAIL-induced apoptosis was assayed by
measurement of DNA fragmentation. Comparable to the
CD95L-induced apoptosis assays, the VMCub1 and SD
c-FLIPL/S double knockdown cells as well as the SD c-FLIPL
single knockdown cells showed elevated levels of apoptosis
upon TRAIL stimulation (Figures 5a and b). To assess activa-
tion of caspase-8 and caspase-3, cells were stimulated with
TRAIL for up to 24h. The cleavage products of caspase-8
and caspase-3 were readily detected in the VMCub1
c-FLIPL/S double knockdown cells upon TRAIL stimulation,
indicating activation of both caspases (Figure 5c). Small
amounts of both processed caspases could also be detected
in VMCub1 cells expressing shRNAs targeting c-FLIPL or
c-FLIPS alone, suggesting that the c-FLIP isoforms are
not complementary. In SD cells, the cleavage products p18/
41/43 of caspase-8 and p17/20 of caspase-3 were clearly
Figure 2 Urothelial carcinoma cell lines VMCub1 and SD are sensitised to apoptosis by CHX. (a and b) For analysis of apoptosis sensitivity, urothelial carcinoma cells
were left untreated or stimulated for 16h with the indicated concentrations of CD95L (a) or TRAIL (b) in the presence or absence of 10mg/ml CHX. The amount of apoptotic
cellswas determinedby quantiﬁcation of sub-G1DNAcontentby ﬂow cytometry.Measurements are displayedas themean ofat leastthree independent experiments±S.D.
(candd)VMCub1andSDcellswereleftuntreatedorstimulatedforthetimesasindicatedwith0.4ng/mlCD95L(c)or25ng/mlTRAIL(d)inpresenceorabsenceof10mg/ml
CHX. Cleavage of caspase-8 and caspase-3 was analysed by western blot with b-actin as the loading control
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single knockdown cells. Moreover, the proform of both
caspase-8 and caspase-3 was extensively degraded in SD
cells expressing shRNAs targeting both c-FLIPL and c-FLIPS
at later time points (Figure 5d). In contrast, both caspases
remained uncleaved in VMCub1 and SD cells stably
transduced with scramble shRNAs, suggesting that c-FLIP
proteins confer broad resistance to death receptor activation
in urothelial carcinoma.
Discussion
Resistance to cell death is one hallmark of cancer cells.
1
Accordingly, proapoptotic factors such as Bax are often
downregulated in tumours, whereas anti-apoptotic molecules
suchasBcl-2,Bcl-xLorIAPstendtobeupregulated.Similarly,
high c-FLIP expression has been observed in various
cancers, for example, in Hodgkin’s lymphoma
17,18 and
melanoma.
4 It is therefore intriguing that we observed a lower
expression of the c-FLIPL isoform in urothelial tumour tissues
compared with normal tissues, which was recapitulated in
frequency and extent in urothelial carcinoma cell lines
compared with NUCs. To our knowledge, there is only one
previousstudyofc-FLIPexpressioninbladdercancertissues,
which was performed by immunohistochemistry.
28 These
authors observed c-FLIP expression in 81% of 53 studied
urothelialcancers,predominantlyincaseswithhigherT-stage
and worseclinical course. Itisbit curious thatc-FLIP couldnot
be detected in 20% of the cancers and normal urothelium by
immunohistochemistry in this study, as in our hands c-FLIP
protein and its according mRNA was detectable in all
carcinoma cell lines and in NUCs. Interestingly, in the study
Figure 3 Overexpression of c-FLIP isoforms protects urothelial carcinoma cells against apoptosis. (a) VMCub1 and SD cells were treated with 10mg/ml CHX for up to
24h. c-FLIP protein expression was determined by western blotting. b-Actin served as a loading control. (b) Original pEF-vectors and the generated pIRES2EGFP-c-FLIP
constructs were transiently transfected into 293T cells. The c-FLIP and GFP protein expression was analysed by western blotting with tubulin as the loading control.
(c–f) pIRES2EGFP-c-FLIP constructs were transiently overexpressed in VMCub1 cells (c and d) or SD cells (e and f). The urothelial carcinoma cells were left untreated
or stimulated with 1ng/ml CD95L for 4h. Sensitivity to apoptosis in transfected cells was analysed by ﬂow cytometry. Intracellular staining of active caspase-3 was used
as a marker for apoptotic cells and the transfected cells were identiﬁed by GFP expression. (c and e) Histograms are representative for three independent experiments
with percentages shown for stimulated samples. (d and f) Data are shown as the percentages within the GFP-positive population with the mean of three independent
experiments ±S.D.
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Cell Death and DiseaseFigure4 Knockdownofc-FLIPLandc-FLIPSsensitisesurothelialcarcinomacellstoCD95L-inducedapoptosis.(aandb)Foranalysisofapoptosissensitivity,VMCub1(a)
or SD cells (b) stably transduced with the indicated shRNAs against c-FLIPL, c-FLIPS or both isoforms (c-FLIPL/S) were left untreated or stimulated for 16h with the indicated
concentrations of CD95L. The amount of apoptotic cells was quantiﬁed by DNA fragmentation analysed by ﬂow cytometry. Data are shown as the mean of four
measurements±S.D. Statistical analyses was performed by two-tailed Mann–Whitney U-tests, The symbol * indicates Po 0.05 with respect to scramble controls. (c and d)
VMCub1(c)andSD(d)cellswereleftuntreatedorstimulatedwith0.4ng/mland0.8ng/mlCD95L,respectively,forthetimesindicated.Cleavageofcaspase-8andcaspase-3
was analysed by western blot. Expression of b-actin is presented as the loading control
Figure 5 Effect of c-FLIP isoform knockdown on the susceptibility of urothelial carcinoma cells to TRAIL-induced apoptosis. (a and b) VMCub1 (a) or SD cells (b) with
knockdown of c-FLIPL, c-FLIPS or both isoforms (c-FLIPL/S) were left untreated or stimulated with 25ng/ml TRAIL for 24h. The amount of apoptotic cells was quantiﬁed by
measuringthesub-G1DNAcontentbyﬂowcytometry.Dataareshownasthemeanofatleastthreemeasurements±S.D.(candd)Foranalysisofcaspase-8andcaspase-3
cleavage,VMCub1(c)andSDcells(d)wereleftuntreatedorstimulatedwith25ng/mlTRAILfor thetimesasindicated.Lysateswereanalysedbywesternblotwithb-actinas
the loading control
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28 concurrent expression of CD95,
CD95L and c-FLIP was observed in 22 cases, suggesting a
function of c-FLIP in protecting the tumours against CD95-
mediated apoptosis. Our present study provides direct
evidence for this function. Speciﬁc downregulation of c-FLIP
by RNA interference using shRNAs sensitised urothelial
carcinoma cell lines towards both CD95L- and TRAIL-
mediated apoptosis. Consistently, a function of c-FLIP in
resistance to TRAIL has been observed by others.
29
Although independent studies on c-FLIP mRNA and protein
expression in tissue samples may be helpful, it will likely
remain difﬁcult to distinguish the different c-FLIP isoforms in
tissue samples by immunohistochemistry. Our ﬁnding that
they are differentially expressed in urothelial carcinoma
accentuates the question as to their individual function. The
twosplicevariantsc-FLIPLandc-FLIPSinhibitdeathreceptor-
mediated apoptosis by different mechanisms
12 and can even
have opposing functions on cell death.
15,16 In contrast to
lymphoid cells, in which c-FLIPS has a dominant role in
protection against CD95-mediated apoptosis,
33 our data
suggest that the short isoform has a more auxiliary function
in urothelial carcinoma. In the SD model system, isoform-
speciﬁc knockdown of c-FLIPL was sufﬁcient to sensitise cells
for apoptosis induction by death ligands. Importantly, knock-
down of both isoforms in SD cells resulted in similar apoptosis
levelsasco-treatmentwith CHX,suggestingthatc-FLIP isthe
major short-lived anti-apoptotic protein in these cells. In
VMCub1 cells, however, single knockdowns did not sensitise
for apoptosis and complete inhibition of c-FLIP expression
resulted in partial sensitisation compared with CHX
co-treatment, indicating that additional factors contribute to
apoptosis resistance in this cell line. Of note, we detected
elevated expression of Bcl-2 and Bcl-xL in VMCub1 cells,
which may contribute to resistance against death receptor-
mediated apoptosis.
Our observation that c-FLIPL is downregulated in urothelial
carcinoma appears counterintuitive at ﬁrst as one would
expect that high expression of an anti-apoptotic molecule is
generally beneﬁcial for tumour cell survival. However, apart
from apoptosis induction, signalling through CD95 exerts
additional functions, especially in resistant cells. Thus, CD95
in some instances promotes tumour growth as well as motility
and invasiveness of tumour cells.
34,35 These functions are
mediatedbyactivationoftheNF-kBandJNKpathways,which
have been shown to be inhibited by high c-FLIP expres-
sion.
34,36,37 Therefore, cancer cells may have to ﬁne-tune
c-FLIP expression to balance apoptosis resistance on the one
hand with non-apoptotic death receptor signalling via NF-kB
and other pathwayson the other hand.Moreover, c-FLIPLhas
been shown to have a dual role in apoptosis signalling being
anti-apoptotic at high expression levels and proapoptotic at
low expression levels.
16 Even more complicated, c-FLIPL
acquiresproapoptoticfunctioninthepresenceofhighc-FLIPS
expression. Thus, as they also express c-FLIPS, urothelial
carcinoma cells may beneﬁt from downregulation of c-FLIPL
by preventing its proapoptotic activity. Finally, an optimal
c-FLIPL and c-FLIPS expression level and ratio may be
required to prevent activation of the Ripoptosome, a recently
described cell death-initiating multiprotein complex.
38,39
Depending on its molecular composition, the Ripoptosome
initiates either apoptosis or necroptosis. Activation of the
kinases RIP1 and RIP3 leads to necroptosis, whereas their
inactivation by caspase-8-mediated cleavage favours apop-
tosis. Importantly, c-FLIPS inhibits caspase-8 activity within
the Ripoptosome and may, therefore, promote necroptosis.
38
In contrast, caspase-8 and c-FLIPL inhibit necroptosis, a cell
death mode, which leads to inﬂammation. As the recruited
inﬂammatory cells may result in tumour cell elimination,
blocking Ripoptosome function by c-FLIPL may be important
for urothelial carcinoma development.
Taken together, we have shown that c-FLIP, and in
particular the c-FLIPL splice variant, is an important apoptosis
resistance factor in urothelial carcinomas. Therefore, target-
ing c-FLIP in CD95L- or TRAIL-based therapies may be a
promising approach to treat urothelial tumours. Moreover,
c-FLIP may constitute a factor in the development of
resistance against immunotherapy and chemotherapy used
in the treatment of bladder cancer, in so far as their efﬁcacy
depends on activation of death receptors.
Materials and Methods
Patients and tissue samples. Tissue samples were obtained from patients
undergoing cystectomy for urothelial carcinoma at the Department of Urology of
the Heinrich-Heine-University Duesseldorf between 1995 and 2004. Twenty-four
patients were male and seven were female; average age at surgery was 69.9 years
(range 54–94 years). The samples were selected to comprise all stages and
included three tumours each staged as pTa or pT1, 5 staged as pT2, 11 staged as
pT3 and 7 staged as pT4. Lymph node metastases were present in seven patients.
The lymph node status was not determined further for two additional patients with
4pT2 cancers. Eleven cancers were graded as G2 and 20 as G3. Morphologically
normal tissue from 10 patients was used for comparison. The use of patient
tissues was approved by the Ethics Committee of the Medical Faculty of the
Heinrich-Heine-University Duesseldorf.
Cell culture and transient transfections. Urothelial carcinoma cell lines
639v, SD, 647v, VMCub1, BFTC905 and J82 as well as human embryonic kidney
cells (293T) were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM high
glucose; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum
(PAA Laboratories, Coelbe, Germany) and 50mg/ml of each penicillin and
streptomycin (Invitrogen). Transient transfections of 293T, VMCub1 and SD cells
wereperformedwithJetPEI(Polyplustransfection,Illkirch,France)orLipofectamine
2000 reagent (Invitrogen) according to the manufacturer’s instructions. Normal
urothelial cells were isolated and cultured according to the method of Southgate
et al. with slight modiﬁcations as described.
40
Lentiviral infection of cells. c-FLIP MISSION TRC shRNA Target Set
cloned into the lentiviral vector pLKO.1 was purchased from Sigma (Sigma-Aldrich
Chemie, Steinheim, Germany). Generation of c-FLIPshort shRNA was previously
described.
33 Lentiviral vectors were co-transfected with the envelope vector
pMD2.G (Addgene no. 12259) and the gag-pol expression plasmid
pCMV_dR8.2dvpr (Addgene no. 8455) into 293T cells as described in ‘Cell
culture and transient transfections’. Lentiviruses (LVs) were collected 36 and 60h
after transfection. Crude virus was ﬁltered through 0.45mm PVDF ﬁlters (Millipore,
Billerica,MA,USA),concentrated byultracentrifugationat100000 gfor60minat
41C and stored at  801C until further use. Titres were determined by infection of
HeLa cells with serial dilutions of LV stocks and 5mg/ml polybrene (Sigma-Aldrich
Chemie). Speciﬁc knockdown of the various c-FLIP isoforms was veriﬁed by
western blot analysis. SD and VMCub1 cells were infectedby adding LVs and5mg/
ml polybrene to 2 10
6 cells. Cells were centrifuged for 1h at 860g and then
incubated over night. Stably transfected clones were selected by limited dilution in
medium containing 4mg/ml puromycin (Sigma-Aldrich Chemie).
Cloning of c-FLIPL, c-FLIPS and c-FLIPR. c-FLIPL, c-FLIPS and c-FLIPR
were cloned using previously described plasmids
3,6 as PCR templates. PCR
reactionswereperformedwithPhusion
-ﬂashproofreadingpolymerase(Finnzymes,
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TCTGCTGAAGTCATCCA-30;c-FLIPLreverse50-GCCCGGGCTTATGTGTAGGAG
AGGATAA-30; c-FLIPS reverse 50-GCCCGGGCTCACATGGAACAATTTCCAA-30;
c-FLIPR reverse 50-GCCCGGGCTCATGCTGGGATTCCATATG-30. Thereafter
cloning into the expression vector pIRES2EGFP (Clontech, Mountain View,
CA, USA) was performed by using restriction digestion with SmaI and NheI
(New England Biolabs, Ipswich, MA, USA).
Western blot analysis. For western blot analysis, cells were lysed in TPNE
buffer (PBS adjusted to 300mM NaCl, 1% Triton-X100, 2mM EDTA, 1mM PMSF
and 1mg/ml each of leupeptin, aprotinin, chymostatin and pepstatin A). Twenty
micrograms of postnuclear supernatant protein as determined by the BCA method
(Pierce Biotechnology, Rockford, IL, USA) were separated by 12% SDS-PAGE,
blotted onto a PVDF membrane (Amersham, Freiburg, Germany) and blocked with
5% non-fat dry milk in TBS/Tween (0.05% Tween-20 in TBS). The blots were
washed with TBS/Tween and were thereafter incubated with speciﬁc antibodies
overnightat 41C. The following day, blots were washed with TBS/Tween, incubated
with horseradish peroxidase-coupled secondary antibodies (1:20000) for 1h at
roomtemperature,washedagainanddevelopedwithachemiluminescencereagent
(Pierce Biotechnology). For stripping, blots were incubated in Re-Blot mild solution
(Millipore) according to the manufacturer’s protocols.
The antibodies used for western blotting were b-actin (AC-74; Sigma-Aldrich
Chemie), caspase-3 (CPP32; R&D Systems, Minneapolis, MN, USA), cleaved
caspase-3 (Asp175; Cell Signalling Technology, Danvers, MA, USA), caspase-8
(12F5; kind gift of Dr. K Schulze-Osthoff, Tuebingen,Germany),caspase-7(Sigma-
Aldrich Chemie), c-FLIP (NF6; Enzo Life Sciences, Loerrach, Germany), Bcl-xL
(clone 44) and XIAP (clone 48; BD Biosciences, Heidelberg, Germany).
Furthermore, anti-FADD (1F7), anti-Bax (6A7) and anti-Bak were purchased from
Upstate (Hamburg, Germany). Anti-Bcl-2 (C-2) and HRPO-conjugated goat anti-
rabbit IgG were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). HRPO-
conjugated goat anti-rat IgG, donkey anti-goat IgG, goat anti-mouse IgG1, IgG2a
and IgG2b were from Southern Biotechnology Associates (Birmingham, AL, USA)
Quantitative real-time PCR. Total RNA was isolated from 5–10 10
6 cells
with the RNeasy kit (Qiagen, Hilden, Germany). Real-time PCR was carried out on
an Applied Biosystems 7300 Real-Time PCR system using the QuantiTect SYBR
Green RT-PCR Kit (Qiagen) according to the manufacturer’s instructions.
Measurements were run in triplicates and normalised to GAPDH or TBP values.
Ampliﬁcation primers for real-time PCR are as follows:
c-FLIPL forward 50-CCTAGGAATCTGCCTGATAATCGA-30;
c-FLIPL reverse 50-TGGGATATACCATGCATACTGAGATG-30;
c-FLIPS forward 50-GCAGCAATCCAAAAGAGTCTCA-30;
c-FLIPS reverse 50-ATTTCCAAGAATTTTCAGATCAGGA-30;
GAPDH forward 50-ATCACCATCTTCCAGGAGCGAGATC-30;
GAPDH reverse 50-GGCAGAGATGATGACCCTTTTGGC-30;
TBP forward 50-CGAAACGCCGAATATAATCC-30;
TBP reverse 50-CGTGGCTCTCTTATCCTCA-30.
Flow cytometry assays. Cell surface staining and cytotoxicity assays were
performed as described previously.
30 For assaying apoptosis, 2.5 10
5 cells per
wellwereleftuntreatedorwerestimulatedin6-well-platesfor16hwithCD95Lorfor
24hwithTRAILattheindicatedconcentrations.Thefollowingantibodieswereused
for cell surface staining: TNF-R1 (kind gift of Dr. H Wajant, Wuerzburg, Germany),
TRAIL-R1 (Enzo Life Sciences) and TRAIL-R2 (PE-conjugated; eBioscience,
San Diego, CA, USA). CD95 surface staining was performed with 2R2 antibody
(kind gift of Dr. K Schulze-Osthoff). TNF-R1, TRAIL-R1 and CD95 antibodies
were labelled with PE-conjugated goat-anti-mouse secondary antibody (Jackson
ImmunoResearch, Suffolk, UK). For assaying the effect of c-FLIP overexpression
on apoptosis sensitivity, VMCub1 and SD cells were transiently transfected
(2.5 10
5 cells in 6-well-plates) with empty pIRES2EGFP vector (Clontech) or the
c-FLIPL, c-FLIPS, c-FLIPR constructs (see above). Cells were left untreated or were
stimulated with 1ng/ml CD95L for 4h, followed by intracellular staining of active
caspase-3 (BD Biosciences) or TMRE staining (Enzo Life Sciences) according to
the manufacturer’s manual.
Statistical analysis. All statistical analyses were performed by nonparametric
Mann–Whitney U-tests to determine statistical signiﬁcance using GraphPad Prism
(Graph-Pad-Software Inc., La Jolla, CA, USA). Standard deviation and standard
error of the mean were used as error bars.
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